Skip to content
YORKSTONE
Join

Reference

Reference: molecular weights, conversions, units.

Conversion math, units and peptide reference data. Informational only, never a dosing recommendation.

Not medical advice. Ranges below are what people report logging, not what anyone should take. FDA-approved compounds have their own prescribed dosing on the label.
1 mg= 1,000 mcg
1 mL= 100 u (insulin)
1 cc= 1 mL
5 IU≈ 1.7 mg (rh-GH)
Semaglutide
GLP
4,113.6 Da

GLP-1 receptor agonist. Slows gastric emptying, modulates insulin response, and reduces appetite.

Range people log
0.25–2.4 mg / wk
cadence
weekly SC
half-life
~7 days
FDA-approvedFDA-approved as Ozempic (T2D), Wegovy (weight management), Rybelsus (oral T2D). Off-label use is outside the approved label.
Tirzepatide
GLP
4,813.5 Da

Dual GLP-1 / GIP receptor agonist (Eli Lilly, LY3298176). Approved for type 2 diabetes and for chronic weight management.

Range people log
2.5–15 mg / wk
cadence
weekly SC
half-life
~5 days
FDA-approvedFDA-approved as Mounjaro (T2D), Zepbound (weight management).
Retatrutide
GLP
4,731.5 Da

Triple GLP-1 / GIP / glucagon receptor agonist (Eli Lilly, LY3437943). In phase 3 trials for obesity and type 2 diabetes.

Range people log
1–12 mg / wk
cadence
weekly SC
half-life
~6 days
InvestigationalInvestigational. Phase 3 trials ongoing; not FDA-approved at the time of writing.
BPC-157
Repair
1,419.5 Da

15-amino-acid fragment of a gastric body-protection protein. Studied for tendon, ligament, and gut-lining repair in rodent models.

Range people log
200–500 mcg / day
cadence
daily SC / IM
half-life
~4 hrs
Research peptideNot FDA-approved for any indication. Classified as a research peptide; not for human use under FDA.
TB-500
Repair
~889 Da

Synthetic fragment of thymosin β-4. Studied for soft-tissue repair, angiogenesis, and inflammation modulation.

Range people log
2–10 mg / wk
cadence
2×/week SC
half-life
~2–3 days
Research peptideNot FDA-approved. Classified as a research peptide; not for human use under FDA.
Tesamorelin
GHS
5,135.9 Da

GHRH analog. Stimulates endogenous growth-hormone release rather than supplying exogenous GH.

Range people log
1–2 mg / day
cadence
daily SC
half-life
~26 min
FDA-approvedFDA-approved as Egrifta for HIV-associated lipodystrophy. Other uses are off-label.
CJC-1295
GHS
3,647 Da (DAC) · 3,368 Da (no DAC)

Modified GHRH analog. The "DAC" (drug-affinity complex) variant extends serum half-life; the "no DAC" variant matches natural GHRH pulse timing.

Range people log
100–300 mcg / pulse
cadence
weekly (DAC) · daily (no DAC) SC
half-life
~6 days (DAC) · ~30 min (no DAC)
Research peptideNot FDA-approved. Classified as a research peptide; not for human use under FDA.
Ipamorelin
GHS
711.9 Da

Selective ghrelin / GHS-receptor agonist that stimulates growth-hormone release. Often logged alongside a GHRH analog such as CJC-1295.

Range people log
100–300 mcg / pulse
cadence
1–3×/day SC
half-life
~2 hrs
Research peptideNot FDA-approved. Classified as a research peptide; not for human use under FDA.
MOTS-c
Mito
~2,169 Da

Mitochondrially-encoded peptide. Studied for metabolic regulation, insulin sensitivity, and exercise capacity in animal models.

Range people log
5–10 mg / wk
cadence
2×/week SC
half-life
short (~hrs)
Research peptideNot FDA-approved. Classified as a research peptide; not for human use under FDA.
GHK-Cu
Cosmetic
340.4 Da (peptide) · 403.9 Da (Cu complex)

Copper-binding tripeptide. Researched for wound healing, hair-follicle support, and skin remodeling; widely used in topical cosmetics.

Range people log
1–2 mg / day
cadence
daily topical / SC
half-life
short (~hrs)
Research peptideNo FDA drug approval. Topical cosmetic use is widely commercialized; injectable use is research-only.

Next

Want a compound added?

The reference grows as members ask. Request an addition by email and we review requests every week.

Request a compound